A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 15 Mar 2018 Planned End Date changed from 13 Jul 2020 to 18 Jul 2020.
- 15 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2017 Planned primary completion date changed from 26 Apr 2019 to 13 Jul 2020.